2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson EJ, Madden K, Miller DM, Nghiem P, Pavlick AC, Puzanov I, Rabinowits G, Ruiz ES, Sondak VK, Tavss EA, Tetzlaff MT, Brownell I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. Journal For ImmunoTherapy Of Cancer 2022, 10: e004434. PMID: 35902131, PMCID: PMC9341183, DOI: 10.1136/jitc-2021-004434.Peer-Reviewed Original ResearchConceptsNonmelanoma skin cancerClinical practice guidelinesImmune checkpoint inhibitorsCutaneous squamous cell carcinomaMerkel cell carcinomaBasal cell carcinomaCell carcinomaPractice guidelinesSkin cancerCancer clinical practice guidelinesCancer care professionalsManagement of toxicitiesSpecial patient populationsSquamous cell carcinomaImmunotherapy of cancerConsensus-based recommendationsOwn clinical experienceRoutine clinical useCheckpoint inhibitorsMetastatic diseasePatient selectionPatients' qualityImmunotherapeutic treatmentPatient populationAggressive subtype
2012
Drug targets and predictive biomarkers in the management of metastatic melanoma
Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmacogenomics And Personalized Medicine 2012, Volume 5: 139-148. PMID: 23226069, PMCID: PMC3513235, DOI: 10.2147/pgpm.s25100.Peer-Reviewed Original ResearchMetastatic melanomaPredictive biomarkersApproval of ipilimumabChoice of treatmentImmune system characteristicsFederal Drug AdministrationClinical benefitTherapeutic optionsFatal skin cancerTreatment strategiesDrug combinationsMelanoma treatmentPromising drugAntitumor effectsDrug AdministrationSkin cancerIndividual tumorsMelanomaPersonalized therapyTherapyTreatmentDrug targetsBiomarkersIpilimumabTumors
2008
Suppressor role of activating transcription factor 2 (ATF2) in skin cancer
Bhoumik A, Fichtman B, DeRossi C, Breitwieser W, Kluger HM, Davis S, Subtil A, Meltzer P, Krajewski S, Jones N, Ronai Z. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 1674-1679. PMID: 18227516, PMCID: PMC2234203, DOI: 10.1073/pnas.0706057105.Peer-Reviewed Original ResearchMeSH Keywords9,10-Dimethyl-1,2-benzanthraceneActivating Transcription Factor 2AnimalsApoptosisBeta CateninCarcinogensCell ProliferationCyclin D1DNAEpidermisKeratinocytesMiceMice, KnockoutPapillomaPresenilin-1Proto-Oncogene Proteins c-mybReceptor, Notch1Skin NeoplasmsTetradecanoylphorbol AcetateTissue Array AnalysisTumor Suppressor ProteinsConceptsSkin tumor formationTranscription factor 2Two-stage skin carcinogenesis protocolTumor formationBasal cell carcinomaSkin carcinogenesis protocolFactor 2K14-Cre miceCell carcinomaCarcinogenesis protocolMouse modelBeta-catenin expressionPapilloma developmentSkin cancerExhibit reduced expressionAnchorage-independent growthNormal skinNotch1 expressionCyclin D1MiceReduced expressionSuppressor roleSuppressor activitySelective expressionBasal layer